SALVATORE, LISA
 Distribuzione geografica
Continente #
NA - Nord America 1.290
EU - Europa 448
AS - Asia 263
AF - Africa 38
OC - Oceania 1
Totale 2.040
Nazione #
US - Stati Uniti d'America 1.262
IT - Italia 124
CN - Cina 122
SG - Singapore 95
DE - Germania 88
SE - Svezia 70
BG - Bulgaria 46
GB - Regno Unito 31
CA - Canada 28
FR - Francia 23
VN - Vietnam 21
AT - Austria 18
SN - Senegal 16
RU - Federazione Russa 15
FI - Finlandia 14
CI - Costa d'Avorio 13
TR - Turchia 10
NG - Nigeria 8
IN - India 6
UA - Ucraina 5
HK - Hong Kong 4
NL - Olanda 3
CH - Svizzera 2
JP - Giappone 2
LT - Lituania 2
NO - Norvegia 2
AU - Australia 1
BA - Bosnia-Erzegovina 1
BE - Belgio 1
BJ - Benin 1
CZ - Repubblica Ceca 1
EE - Estonia 1
IL - Israele 1
KR - Corea 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
Totale 2.040
Città #
Woodbridge 231
Fairfield 149
Santa Clara 111
Ashburn 94
Chandler 80
Seattle 71
Houston 69
Cambridge 59
Singapore 56
Ann Arbor 51
Wilmington 48
Sofia 46
Shanghai 44
New York 36
Beijing 30
Pisa 27
Princeton 23
Boardman 21
Ottawa 19
Lawrence 18
Vienna 18
Des Moines 17
Dakar 16
Medford 16
Bremen 14
Abidjan 13
Dong Ket 13
Florence 13
London 13
Dearborn 12
Marseille 12
Istanbul 10
Redwood City 9
Lagos 8
Düsseldorf 7
Frankfurt am Main 7
Nanjing 7
Lancaster 6
Phoenix 6
Seacroft 6
Serra 6
Toronto 6
Changsha 5
Kunming 5
Positano 5
Rome 5
San Diego 5
Turin 5
Boulder 4
Helsinki 4
Hong Kong 4
Lusciano 4
Polverigi 4
San Francisco 4
Shenyang 4
Hebei 3
Leawood 3
Nürnberg 3
Ogden 3
Genoa 2
Guangzhou 2
Hangzhou 2
Lecce 2
Los Angeles 2
Nanchang 2
Oslo 2
Qingdao 2
Quanzhou 2
San Giuliano Terme 2
Tianjin 2
Aprilia 1
Berlin 1
Bern 1
Bracknell 1
Bratislava 1
Brussels 1
Buffalo 1
Capannori 1
Capurso 1
Chengdu 1
Chiswick 1
Cotonou 1
Council Bluffs 1
Cutrofiano 1
Dallas 1
Duncan 1
Esslingen am Neckar 1
Fuzhou 1
Gallarate 1
Geneve 1
Genova 1
Grafing 1
Haifa 1
Hamilton 1
Hefei 1
Indiana 1
Indore 1
Jinan 1
Jüchen 1
Kent 1
Totale 1.640
Nome #
TRIBE-2: A phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group 156
An interview with Alfredo Falcone and Lisa Salvatore: RECOURSE and trifluridine/tipiracil in metastatic colorectal cancer 153
TAS-102 for the treatment of metastatic colorectal cancer 143
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 128
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer 124
Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients 124
TRIPLETE: A randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer 119
Location of primary tumor and benefit from anti-epidermal growth factorreceptor monoclonalantibodies in patients with RAS and BRAF wild-typemetastatic colorectal cancer 113
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 108
KRAS status and risk of venous thromboembolic events in patients with metastatic colorectal cancer: a case-control study. 102
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. 99
null 98
Circulating microRNAs in metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib 87
null 85
Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer 85
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial 85
Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer 72
Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study 55
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer 36
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer 32
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study 32
First-line chemotherapy for mCRC-a review and evidence-based algorithm 31
Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study 30
Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers 3
Totale 2.100
Categoria #
all - tutte 6.803
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.803


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020185 0 0 0 0 0 0 45 38 41 27 23 11
2020/2021162 10 9 5 12 13 5 9 6 40 11 19 23
2021/2022214 3 9 2 3 34 36 4 5 19 13 9 77
2022/2023303 24 48 20 34 31 35 2 14 72 2 18 3
2023/2024179 14 12 26 8 23 28 16 17 4 3 8 20
2024/2025289 5 22 40 28 92 81 21 0 0 0 0 0
Totale 2.100